AKTX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-19

• We are an oncology company developing next generation ADCs designed around novel payload biology. Our platform is anchored by PH1, a spliceosome modulating payload that in preclinical settings has demonstrated cytotoxic activity and robust activation of the immune system to attack cancer. Our busine…

• ●robust activation of the immune system to drive greater and more enduring efficacy in treating cancer sustained duration of response of tumor regression or elimination;

• ●ability to be used in combination with checkpoint inhibitors to potentially deliver synergistic efficacy results (more than additive) to drive potential longer-term cancer remissions;

• ●improved safety and tolerability relative to ADCs that are currently available.

• Our lead product candidate is AKTX-101, a preclinical stage Trop-2-targeting ADC that combines PH1 with a Trop-2 targeting antibody. Trop-2 is an antigen that is expressed in a number of highly incident solid tumors, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostat…

Text removed vs the prior filing · source: 10-Q · 2025-11-13

• We are an oncology company developing next-generation antibody-drug conjugates (“ADCs”) designed around novel proprietary cancer-killing toxins (“payloads”). We believe these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond option…

• ● more effective cancer-killing properties, or cytotoxicity;

• ● activation of the immune system to generate a greater numbers of neoepitopes than currently available ADCs, leading to activation of both B-cells and T-cells in the tumor microenvironment to generate an immune response that has the potential to continue to kill cancer cells in the tumor microenvir…

• ● ability to be used in combination with checkpoint inhibitors to potentially deliver synergistic efficacy results (more than additive);

• ● sustained duration of response of tumor regression or elimination;

Text added vs the prior filing · source: 10-Q · 2026-05-19

• Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties discussed within “Item 1A. Risk Factors” of our Form 10-K, together with all of the other information in this Form 10-Q, including the section “Management’s Discussion and Analysis o…

• We have IPR&D and future impairment of IPR&D may have an adverse impact on our future financial condition and results of operations.

• As of March 31, 2026, we had in-process research and development (“IPR&D”) of approximately $30.3 million, primarily relating to AKTX-101 and our ADC Platform. Our intangible assets have been previously impaired and remain subject to additional impairment analyses whenever an event or change in circ…